An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A person posted that they got their first 2.5 mg injection of Mounjaro (tirzepatide) a few days ago and noticed mild appetite suppression for the first two days. They skipped finishing dinner for the first time in a long while but still thought about food. The effect faded by day three, and they’re hoping for stronger or more consistent effects after a few more doses. Tirzepatide (brand name Mounjaro) is a man-made peptide — think of it as a tiny protein-like molecule — that acts like two natural gut hormones that tell your brain to feel full and help control blood sugar. One of those hormones is similar to what drugs like Ozempic mimic. In plain terms, tirzepatide nudges appetite down and can slow how quickly your stomach empties, which can make you eat less and feel full longer. It’s given by injection under the skin, usually once a week, and doses are typically increased slowly over weeks. What this single-person report shows is an early, mild response: less hunger and not finishing a meal for a couple of days after the first low dose. That’s exactly what clinical studies have seen in larger groups — appetite changes often begin early — but the big effects on weight and appetite generally come after multiple doses and at higher maintenance levels. This anecdote is just one person’s short-term experience at the low starting dose, so it can’t tell us how well it will work long term or how much weight someone will lose. In trials, meaningful weight loss and stronger appetite suppression usually appeared after weeks to months and with higher doses. Why this matters: a lot of people considering Mounjaro want to know how quickly they’ll feel different and whether early mild changes predict bigger results. Early appetite suppression is common and can be encouraging because it suggests the drug is doing something. If you’re starting treatment, expect gradual changes rather than overnight transformation. People tracking food intake or weight might find these early shifts useful for motivation and habit changes. Caveats and risks: this post is anecdote, not a study. Side effects for tirzepatide can include nausea, diarrhea, vomiting, belly pain, fatigue, and low blood sugar in people on certain diabetes drugs. Some people find side effects worse when doses are raised; that’s why prescribers increase the dose slowly. It’s not safe or appropriate for everyone — for example, people with a personal or family history of certain thyroid cancers or certain pancreatitis risks may be advised against it. Regulatory approvals and dosing vary by country and by whether it’s being used for diabetes or for weight management. If someone is considering Mounjaro, they should talk to their clinician about benefits, side effects, and monitoring rather than relying on online anecdotes. Bottom line: early mild appetite changes after a first low dose are common and don’t predict the full effect — give it time, expect gradual improvements, and check in with your doctor about side effects and whether continuing is right for you.
Source: r/Mounjaro